萬順新材(300057.SZ):2021年度擬向金融機構申請不超55億元綜合授信融資
格隆匯 12 月 7日丨萬順新材(300057.SZ)公佈,為滿足業務發展需要,2021年度公司及合併報表範圍內子(孫)公司擬向金融機構申請授信總額不超過人民幣55億元的綜合授信融資(貸款、承兑匯票、貿易融資等)。
上述額度含尚未履行完畢的綜合授信融資合同在內。上述額度在2021年度可以循環使用,無需公司另行出具決議。授權公司及各子(孫)公司法定代表人(香港地區公司授權董事)簽署上述綜合授信融資項下的相關法律文件,並以公司及各子(孫)公司擁有的、產權清晰、合法的財產作為自身綜合授信融資的抵押物或質押物。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.